Diabetes

A comprehensive Translational Platform of in vivo models
for evaluating efficacy in complex metabolic disorders

cvmd-magnifyglass.png

Most Translational Platforms for Diabetes Research

Missed ADA 2017CrownBio has developed unique rodent and non-human primate (NHP) based translational platforms that replicate the human pre-diabetic state, diabetes progression, and development of diabetic complications, and help support transition of new anti-diabetic agents from lead compounds into the clinic.

Key Features

  • Most translational rodent and NHP models of diabetes
  • Replicate all stages of disease progression and associated complications
  • Supported by a comprehensive platform of analytical services
  • Useful for modeling various stages of diabetes and for testing therapeutic interventions at different disease stages

Evaluate Efficacy of Anti-Diabetes Drugs in Rodent and NHP Platforms

Diabetes is a group of metabolic diseases quantified by increased blood sugar levels for a prolonged period of time. The most common form of diabetes is Type 2, a chronic progressive disease, characterized by hyperglycemia due to insufficient insulin production and/or cellular insulin resistance. Type 2 diabetes is largely the result of excess body weight, unhealthy diet, inactivity, and aging; therefore, as worldwide obesity levels increase and lifestyles become more sedentary, Type 2 diabetes rates have reached epidemic proportions.

A key challenge in diabetes research and drug development is that most animal models do not completely mimic the complex states of disease progression and associated complications, thereby limiting their translatability.

CrownBio’s unique rodent and NHP platforms enable predicting human response to drug candidates in anti-diabetes programs. Combined with our CVMD services, we enable clients to test which candidate has the highest chance of success in the clinic and inform strategic go/no-go decisions.

Rodent Models of Diabetes

Conventional Rodent Models of Diabetes

Rodent models of diabetes include conventional models that can be used for comparison with historical data sets. These include:

  • ZDF, ZSF-1 rat models of Type 2 diabetes
  • db/db and ob/ob mouse models of Type 2 diabetes
  • STZ-induced Type 1 diabetes model
  • Spontaneous Type 1 diabetes models (NOD and NRG-Akita mice, BB rat)

The Most Translational Polygenic Rodent Models of Diabetes

Modeling the various disease progression stages in diabetes has been a challenge in the conventional rodent models. CrownBio brings unique highly translational models that overcome this challenge:

fatzo-button.png zdsd-button.png

 

NHP Models of Diabetes

Spontaneously Diabetic NHPs

CrownBio provides the world’s largest collection of spontaneously diabetic NHPs that mirror all aspects of human diabetes progression including late stage disease complications. These are the most clinically translatable animal model of Type 2 diabetes and are an ideal model for:

  • Investigating disease mechanisms
  • Efficacy and PK/PD of anti-diabetic agents in development
  • Evaluating biomarkers
  • Understanding possible adverse effects of therapeutic candidates

Contract Research Services

CrownBio’s extensive list of services support in vivo efficacy evaluation of anti-diabetic agents. We bring over three decades of global scientific expertise in helping you obtain data that help with key drug development decisions.

Study Endpoints for Diabetes Research

  • Pharmacology: Efficacy, PK/PD, non-GLP Tox
  • Lean & Fat Mass (DEXA), BMI, Food & Liquid consumption
  • Biomarker analysis
  • Glucose, HbA1c, Insulin, C-peptide, Lipid Profile, etc.
  • Tolerance tests
    • Glucose (GTT): Glucose disposal rate
    • Insulin (ITT): Insulin sensitivity or resistance
    • Pyruvate (PTT): Hepatic glucose genesis
    • Meal (MTT): Incretin response
  • Graded glucose infusion (GGI): Islet function
  • Glucose and insulin clamps: Glucose disposition and insulin sensitivity
  • Organ functions: Renal, Cardiac, Liver, etc.
  • Ultrasound imaging of NAFLD/NASH
  • Bioanalytical assays

CVMD Webinar